<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01717664</url>
  </required_header>
  <id_info>
    <org_study_id>RHB-104-02</org_study_id>
    <nct_id>NCT01717664</nct_id>
  </id_info>
  <brief_title>Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)</brief_title>
  <acronym>CEASE-MS</acronym>
  <official_title>A Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of Fixed Dose Combination RHB-104 as Add-On Therapy to Interferon Beta-1a in Patients Treated for Relapsing Remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RedHill Biopharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RedHill Biopharma Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that Mycobacterium avium paratuberculosis positive Relapsing
      Remitting MS subjects will have a greater response to Interferon beta-1a therapy plus RHB-104
      than from Interferon beta-1a alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined Unique Active lesions</measure>
    <time_frame>Baseline through Wk 24</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Combined Unique Active lesions</measure>
    <time_frame>Week 24 to Week 48</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in cytokine panel</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in cytokine panel</measure>
    <time_frame>Week 24 to Week 48</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>MAP status as established by polymerase chain reaction (PCR)</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>MAP status as established by polymerase chain reaction (PCR)</measure>
    <time_frame>Week 24 to Week 48</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Relapses</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Relapses</measure>
    <time_frame>Week 24 to Week 48</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>Week 24 to Week 48</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>T2-hyperintense lesions</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>T2-hyperintense lesions</measure>
    <time_frame>Week 24 to Week 48</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>T1 post-gadolinium lesions</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>T1 post-gadolinium lesions</measure>
    <time_frame>Week 24 to Week 48</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Burden of Disease</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Burden of Disease</measure>
    <time_frame>Week 24 to Week 48</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Baseline through Week 24</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>RHB-104</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 RHB-104 capsules administered orally BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RHB-104</intervention_name>
    <description>95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
    <arm_group_label>RHB-104</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged ≥18 years

          -  Signed fully informed consent provided as per this protocol and willing to comply with
             the required scheduled assessments of the protocol.

          -  Diagnosis of relapsing-remitting multiple sclerosis (McDonald Criteria (2010)) with
             dissemination in time and space.

          -  Currently treated with a stable dose of Rebif®, or Avonex® for a minimum of 3 months
             duration prior to the screening visit.

          -  Active MS with history of at least one flare within the past 12 months or two flares
             in the past 24 months prior to screening.

          -  An Expanded Disability Status Scale (EDSS) of 6.0 or less at the screening visit.

          -  White blood cell count ≥ to 3.5x109.

          -  Subject agrees to use barrier contraceptive methods (i.e. diaphragm, cervical cap,
             contraceptive sponge or condom) with spermicidal foam/gel/cream/suppository, or IUD
             from study enrolment through 6 weeks after last dose of study medication, unless
             subject is post-menopausal or otherwise incapable of becoming pregnant by reason of
             surgery or tubal ligation, or has had a vasectomy. Subject agrees to appropriate
             contraception method though completion of study.

        Exclusion Criteria:

          -  Treatment with any other biological therapies including but not limited to Interferon
             beta-1b, natalizumab, anti-TNF biologic agents, or other agents intended to reduce TNF
             ≤ 8 weeks prior to screening or within 5 half-lives of agent prior to screening,
             whichever is longer.

          -  Previous treatment with rifabutin and/or clofazimine.

          -  Previous treatment with amiodarone.

          -  Oral or parenteral antibiotics in the 4 weeks prior to screening. (Topical antibiotics
             are permitted.)

          -  Use of Methylprednisolone sodium succinate, prednisone, or any other corticosteroid
             during the 30 days prior to screening.

          -  Relapse within the 30 days prior to screening, or between screening and baseline.

          -  Initiation or dose modification of 4-aminopyridine within 60 days of screening.

          -  Use of azathioprine, 6-mercaptopurine (6-MP), methotrexate, cyclosporine or
             mycophenolate (CellCept) within 8 weeks prior to screening.

          -  Use of glatiramer acetate, cyclophosphamide, or plasma exchange within 12 weeks prior
             to screening.

          -  Use of mitoxantrone within one year prior to screening.

          -  Any previous treatment with cladribine, T cell vaccine, or altered peptide ligand.

          -  Previous total body irradiation or total lymphoid irradiation.

          -  Treatment with any medication that causes QT prolongation or Torsades de Pointes
             within 7 days prior to initiation of study drug, including but not limited to:
             Cisapride, pimozide, astemizole, terfenadine, ergotamine, dihydroergotamine,
             quinidine, procainamide, disopyramide, sotalol, ibutilde, dofetilide, dronedarone,
             ondansetron or other 5-HT3 receptor agonists, citalopram dose greater than 20 mg/day,
             tolteridine and quinine.

          -  Treatment with the following medications within 7 days prior to initiation of study
             drug: colchicine, roflumilast, apixabin, latuda, nefazodone, buspirone, fluvoxamine,
             simvastatin, lovastatin, atorvastatin, amlodipine, diltiazem, felodipine, nifedipine,
             nitrendipine, nisoldipine, fluconazole, ketoconazole, voriconazole, St. Johns wort,
             grapefruit juice, antiretroviral agents, alprazolam, alfentanyl, aprepitant,
             aripiprazole, cyclosporine, boceprevir, carbamazepine, haloperidol, digoxin,
             propranolol, carvedilol, metoprolol, and estrogens.

          -  Adverse reaction or hypersensitivity to the study drug or any medications related to
             the study drug.

          -  Clinically significant abnormalities of hematology or chemistry at screening as
             confirmed by repeat testing based on investigator's discretion, including but not
             limited to, elevations greater than 2 times the upper limit of normal of Aspartate
             Aminotransferase (AST), Alanine Aminotransferase (ALT), or creatinine clearance less
             than 60 ml/min at screening.

          -  Serum potassium, magnesium or calcium outside the normal reference range considered
             clinically significant by the investigator.

          -  Positive stool results for C. difficile.

          -  A positive serology for Hepatitis B, Hepatitis C or HIV at screening except for the
             following:

        If positive history of previously treated Hepatitis C, but HCV PCR is undetectable off
        medications for at least 6 months prior to screening, and treating hepatologist or
        infectious disease specialist believes the subject is cured - subject may be enrolled

          -  One of the following:

        History of atypical mycobacterial infections (other than MAP). History of active
        tuberculosis (TB) requiring treatment in the past 3 years. Tuberculosis infection as
        determined by a positive diagnostic TB test result (defined as a positive or indeterminate
        (after two independent tests) quantiFERON TB Test Gold test).

          -  Currently diagnosed or history of uveitis confirmed by either an ophthalmologist or
             optometrist.

          -  Any evidence of any other significant hematological, hepatic, renal, cardiac,
             pulmonary, metabolic, thyroid, neurological or psychiatric disease that might
             interfere with the subject's ability to safely enter and or complete the study
             requirements.

          -  History of malignancy within the past five years except for basal cell carcinoma of
             the skin or carcinoma in situ of the cervix that has been treated with no evidence of
             recurrence.

          -  Males who do not use barrier contraceptive methods (i.e. condom) with spermicidal
             foam/gel/cream/suppository or have not had a vasectomy.

          -  Females who:

               1. have a positive pregnancy test

               2. are lactating

          -  Refusal to sign the study informed consent form.

          -  Inability to adequately communicate with the investigator or their respective designee
             and/or comply with the requirements of the entire study.

          -  History of drug or alcohol abuse within the past 3 years.

          -  Participation in any experimental drug protocol within 12 weeks of date of screening.

          -  Cardiac pacemaker or any other type of metal implant or any other contraindication for
             MRI (including known allergy to gadolinium).

          -  QTc greater than 440ms, bundle branch block, or major ST or T wave abnormalities that
             make the assessment of the QT impossible.

          -  History of unstable cardiac syndromes including unstable angina, coronary artery
             bypass graft, myocardial infarction or coronary stenting within 2 months of screening;
             NYHA Class 3-4 CHF; history of ventricular tachycardia, ventricular fibrillation,
             personal or family history of sudden death, Long QT Syndrome, or Torsade de Pointes;
             HR&lt;50BPM; having taken any Class 1 or Class 3 antiarrhythmic medications or medicines
             known to prolong the QT interval or be associated with Torsade de Pointes.

          -  Treatment with medical cannabis in the 4 weeks prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ira N Kalfus, MD</last_name>
    <role>Study Director</role>
    <affiliation>RedHill Biopharma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Radi Shahien, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ziv Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RedHill MS Clinical Trial Site 002</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RedHill MS Clinical Trials Site 001</name>
      <address>
        <city>Zefat (Safed)</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2012</study_first_submitted>
  <study_first_submitted_qc>October 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2012</study_first_posted>
  <last_update_submitted>July 27, 2016</last_update_submitted>
  <last_update_submitted_qc>July 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsing Remitting Multiple Sclerosis</keyword>
  <keyword>MAP</keyword>
  <keyword>antibiotic</keyword>
  <keyword>Interferon beta 1-a</keyword>
  <keyword>MS</keyword>
  <keyword>MRI</keyword>
  <keyword>EDSS</keyword>
  <keyword>relapse rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

